Phase 2 N=15 The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
End Stage Renal Disease
Primary: Change in Plasma Concentration Measure of Indoxyl Sulphate (IS) — -25.31; 9.71 µM/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Phase 2 N=40 Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Adult Solid Neoplasm · Childhood Solid Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: The Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose of Temozolomide and Talazoparib Combination Therapy — 0; 0; 1; 2…
N/A N=194 One-month Clinical Evaluation of Oté Sensation Multi-Purpose Solution Care System
Myopia · Hyperopia
Primary: Comfort — 8.44; 8.11 score on a scale
Phase 2 N=8 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
Uveitis
Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants
Phase 2 N=69 Effects of Metformin During Nicotine Withdrawal
Smoking · HIV-1-infection
Primary: Mood Following 24h of Smoking Abstinence — 36.5; 33.8; 37.9; 14.3 score on a scale
N/A N=21 Adjustment of Mask Pressure, for Bilevel Positive Airways Pressure Therapy, by Automated Algorithm
Respiratory Insufficiency · Sleep Disordered Breathing
Primary: Index of Apneoas Plus Hypopnoeas Per Hour of Sleep (AHI) — 1.3; 1.7 Events per hour of sleep
N/A N=3 PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
Sarcoma
Primary: PET Activity Estimates at Midpoint of Treatment as Compared to Baseline — .44 SUV
Phase 3 N=627 A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) at Week 18 — 40.3; 44.6 Percentage of participants
N/A N=178 A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
Idiopathic Pulmonary Fibrosis · Interstitial Lung Disease
Primary: Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home…
Phase 2 N=72 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Postmenopausal Women · Locally Advanced Metastatic Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Overall Response Rate (ORR) — 37.2 Percentage of Participants
Phase 2 N=160 Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer Disease
Primary: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) — 100.0; 100.0; 93.8; 92.9 percentage of participants
Phase 2 N=37 Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome
Gastric Cancer · Gastric Neoplasms
Primary: Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1)…
Phase 2 N=456 Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Heart Failure
Primary: Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12 — -0.28; -0.265; -0.32; -0.353 log-transformed picograms per…
Phase 4 N=84 Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
Cardiovascular Diseases
Primary: Change in Left Ventricle-end Systolic Volume (ESV) — -26.6; -0.5 ml